Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study (Q80841772)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

Mucin 16, cell surface associated

3 January 2020

main subject

1 reference

J M Riedinger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

N Eche

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

J P Basuyau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

I Dalifard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

K Hacene

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

M F Pichon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

7 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

194-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

CA 125 regression: a model for epithelial ovarian cancer response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.035

10.1016/J.YGYNO.2008.01.035

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18329083%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference